Quercetin supplementation attenuates muscle wasting in cancer-associated cachexia in mice by Levolger, S. (Stef) et al.





muscle wasting in cancer-associated
cachexia in mice
Stef Levolger, Sandra van den Engel, Gisela Ambagtsheer,
Jan N.M. IJzermans and Ron W.F. de Bruin∗
Department of Surgery, Erasmus MC – University Medical Center, Rotterdam, The Netherlands
Abstract.
BACKGROUND: Quercetin is a flavonoid with reported antioxidant, anti-inflammatory and anti-aging effects, and may
limit muscle wasting in cancer cachexia.
OBJECTIVE: To investigate the effect of quercetin on muscle wasting in the murine C26 cancer-cachexia model and assess
the feasibility of non-invasive micro-CT analysis of skeletal muscle.
MATERIALS AND METHODS: Custom CRM(P) diets supplemented with 250 mg/kg quercetin (Q) were obtained. Thirty
CD2F1 mice were equally randomized to non-tumor-bearing (NTB), C26 tumor-bearing (TB), TB + Q. All groups started their
allocated diet and underwent hindlimb micro-CT. Bodyweight, food intake, and grip-strength were recorded periodically.
After 21 days, repeat micro-CT was performed. Gastrocnemius (GCM) and tibialis anterior (TA) muscles were resected.
mRNA expression of MuRF1, Atrogin-1, myogenin, and MyoD was determined.
RESULTS: NTB and TB + Q gained 9.4% and 5.3% bodyweight respectively, TB lost 3.9%. Hind limb skeletal muscle
volume remained stable for NTB and TB + Q, whereas TB decreased from 242.0 mm3 to 212.8 mm3. Mean GCM muscle
weight was 175.2 mg (NTB), 171.3 mg (TB + Q) versus 125.5 mg (TB). A tendency towards decreased expression of atrogin-1
and MuRF1 was observed in TB + Q.
CONCLUSION: Dietary quercetin supplementation limits bodyweight loss and muscle wasting in the C26-cancer-associated
cachexia model.
Keywords: Quercetin, cachexia, cancer, muscle wasting
1. Introduction
Progressive muscle wasting is a characteristic
feature of cachexia commonly observed in cancer
patients [1]. This multi factorial syndrome cannot
be fully reversed by conventional nutritional sup-
port and leads to progressive functional impairment
[1, 2]. Up to 50 percent of all cancer patients are
faced with cachexia during the course of their dis-
ease and up to 20 percent of all cancer-associated
deaths may be attributed to cachexia [3–5]. The eti-
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ology of cancer cachexia is not yet fully understood,
however catabolic pro-inflammatory cytokines are
suggested to be of key importance. The most fre-
quently described cytokines associated with cachexia
include interleukin-6 (IL-6), tumor necrosis fac-
tor alpha (TNF-), interferon gamma (IFN-), and
interleukin-1-beta (IL-1B) [6–8].
Treatment of cancer cachexia may be directed
at reduction of synthesis or blocking the action of
the aforementioned pro-inflammatory cytokines. By
doing so, it may contribute to improving the patient
quality of life and, possibly, even prolong survival
[9]. Not just the development of novel pharmaceuti-
cal strategies has been suggested to limit the activity
of catabolic cytokines in cancer cachexia, but also
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dietary interventions have been proposed [9]. For
instance dietary supplementation with long-chain
omega-3 fatty acid eicosapentaenoic acid (EPA)
in cachectic patients appeared promising in initial
studies [10]. Later studies, however, conclude that
there is insufficient evidence to support the clini-
cal application of EPA for the treatment of cancer
cachexia [11, 12]. In contrast, the leucine metabolite
-hydroxy--methyl-butyrate (HMB) limits muscle
wasting in experimental cachexia [13–15] and has
been found to attenuate muscle loss in a clinical
trial [16, 17]. Additionally, quercetin has recently
been described as to limit muscle wasting in vivo
[14]. Quercetin is a plant pigment (flavonoid). It is
found in many vegetables, herbs, and fruits such
as capers, dill, cilantro, red onion, broccoli, berries,
and apples [18]. Its antioxidant, anti-inflammatory,
and anti-aging effects have previously been described
[19–22]. Quercetin supplementation decreases circu-
lating markers of inflammation [23]. In both an APC
knockout cachexia model as well as an obesity model
quercetin supplementation limited associated loss of
muscle mass [14, 24].
In this current study, we sought to investigate the
potential of quercetin in the C26 adenocarcinoma
cancer cachexia model, a well-established model of
cancer cachexia in mice [25], and assess the feasibil-
ity of micro-CT analysis as a novel non-invasive and
potentially supplemental technique of skeletal muscle
measurement.
2. Materials & methods
2.1. Animal ethics committee approval
All animal experiments were performed with the
approval of the Erasmus MC, Rotterdam, the Nether-
lands Animal Ethics Committee and in accordance to
the Dutch National Experiments on Animal Act, and
complied with the EU adopted Directive 86/609/EEC
(1986).
2.2. Animals
Thirty male CD2F1 (BALB/c × DBA/2) F1 mice
of 8 weeks (∼25 grams) were obtained from Charles
River, Maastricht, the Netherlands. Upon arrival, ani-
mals have been housed in individually ventilated
cages and maintained at 22◦C under a 12 h light-dark
cycle with ad libitum access to CRM (P) chow (Spe-
cial Diet Services, Witham, Essex, UK) and water
(n = 3–4 animals per cage). Animals were acclima-
tized for one week prior to the start of the experiments.
2.3. Quercetin
Quercetin was obtained from Sigma-Aldrich,
Zwijndrecht, the Netherlands (product code Q4951
SIGMA) and after arrival at our institution immedi-
ately shipped through to Special Diet Services for the
purpose of manufacturing a custom quercetin supple-
mented diet.
2.4. CRM(P) chow
CRM (P) chow with and without supplemented
quercetin was obtained from Special Diet Services,
Witham, Essex, UK. Diet composition is detailed in
Table 1. A concentration of 250 mg quercetin per kg
chow was manufactured for purpose of this study.
This concentration corresponds with an expected
daily intake of 35 mg per kg of body weight per mouse
per day. All mice started with their allocated diets on
the first day of the experiment.
2.5. C26 Tumor-bearing mice
Colon-26 (C26) adenocarcinoma cells (kindly pro-
vided by Dr. D.O. McCarthy, Ohio State University,
Columbus, OH, USA) were maintained in RPMI
1640 (Westburg BV, Leusden, The Netherlands)
supplemented with 10% fetal bovine serum (FBS,
Sigma-Aldrich, St. Louis, The United States of Amer-
ica), and 1% penicillin/streptomycin (P/S, Fisher
Scientific, Waltham, The United States of America)
at 37◦C in a 5% carbon dioxide environment. On
the first day of the experiment, animals allocated to
tumor-bearing (TB) groups received a subcutaneous
(SC) inoculation in the right flank with 0.5 × 106 C26
adenocarcinoma cells in 100 L sterile PBS under
anesthesia by isoflurane inhalation (5% isoflurane
induction). This is a well-established model of cancer
cachexia in mice [25].
2.6. Assessment of grip-strength
Combined hind- and forelimb grip strength was
measured twice per week by placing the animal on
a grid attached to a force gauge (BIOSEB, Chav-
ille, France), and steadily pulling the mice by the tail
along the sensor axle until grip is released. Maxi-
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Table 1
Rat and mouse breeder and grower diet, pelleted (CRM(P))
Nutrients Total Of which added*
Proximate analysis
Moisture (l) % 10.00
Crude oil % 3.36
Crude protein % 18.35
Crude fiber % 4.23
Ash % 6.27
Nitrogen free extract % 57.39
Digestibility coefficients
Digestible crude oil % 3.05
Digestible crude protein % 16.44
Carbohydrates, fiber and non-starch polysaccharides (NSP)








Gross energy Mj/kg 15.01
Digestible energy Mj/kg 12.27
Metabolizable energy Mj/kg 11.19
At water fuel energy (AFE) Mj/kg 13.93
AFE from oil % 9.08
AFE from protein % 42.37
AFE from carbohydrate % 68.90
Fatty acids
Saturated fatty acids
C12 : 0 Lauric % 0.03
C14 : 0 Myristic % 0.14
C16 : 0 Palmitic % 0.33
C18 : 0 Stearic % 0.06
Monosaturated fatty acids
C14 : 1 Myristoleic % 0.02
C16 : 1 Palmitoleic % 0.10
C18 : 1 Oleic % 0.87
Polyunsaturated fatty acids
C18 : 2(ω6) Linoleic % 0.96
C18 : 3(ω3) Linolenic % 0.11
C20 : 4(ω6) Arachidonic % 0.11
C22 : 5(ω3) Clupanodonic %
Amino acids
Arginine % 1.19
Lysine % 1.04 0.17
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Table 1
(Continued)
Nutrients Total Of which added*
Aspartic acid % 1.00







Calcium % 0.83 0.72
Total phosphorus % 0.64 0.19
Phytate phosphorus % 0.23
Available phosphorus % 0.41 0.19
Sodium % 0.27 0.22
Chloride % 0.40 0.35
Potassium % 0.69
Magnesium % 0.22 0.01
Micro minerals
Iron mg/kg 130.65 60.21
Copper mg/kg 16.42 6.90
Manganese mg/kg 91.05 44.90
Zinc mg/kg 86.59 52.86
Cobalt g/kg 494.92 420.30
Iodine g/kg 390.43 310.17




Retinol g/kg 5218.35 4500.38
Vitamin A iu/kg 17376.38 15001.26
Cholecalciferol g/kg 76.94 75.00
Vitamin D iu/kg 3077.42 3000.00
-Tocopherol mg/kg 93.03 72.81
Vitamin E iu/kg 102.81 80.09
Vitamin B1 (Thiamine) mg/kg 15.84 9.83
Vitamin B2 (Riboflavin) mg/kg 13.28 11.76
Vitamin B6 (Pyridoxine) mg/kg 17.65 13.74
Vitamin B12 (Cyanocobalamin) g/kg 78.17 75.00
Vitamin C (Ascorbic acid) mg/kg 1.80
Vitamin K (Menadione) mg/kg 185.05 180.00
Folic acid (Vitamin B9) mg/kg 4.30 2.94
Nicotinic acid (Vitamin PP) mg/kg 78.92 27.65
Pantothenic acid (Vitamin B3/5) mg/kg 25.24 11.56
Choline (Vitamin B4/7) mg/kg 899.51 75.63
Inositol mg/kg 2253.88 12.78
Biotin (Vitamin H) g/kg 488.74 230.85
The control diet used in the current study is the rat and mouse breeder and grower diet, pelleted (CRM(P)), obtained from Special Diet
Services (SDS). *Added nutrients from manufactured and mined sources. Ingredients (wheat, wheat feed, barley, de-hulled extracted toasted
soya, maize, macro minerals, soya oil, potato protein, hydrolyzed wheat gluten, full fat soya, maize gluten meal, vitamins, micro minerals,
amino acids) and the calculated analysis in the table above are retrieved from the SDS CRM(P) product specification sheet [51]. The quercetin
supplemented diet was manufactured with the addition of 250 mg quercetin per kg chow to the base diet detailed in this table.
mum strength produced before releasing the grid was
registered in triplicate with one minute rest period
for each animal. Obtained values were averaged to
provide a mean force measurement for each indi-
vidual animal and subsequently normalized to each
animal’s grip-strength respectively on day 0. All
measurements were performed blind with respect to
treatment.
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2.7. Skeletal muscle volumetric measurement by
micro-CT
In clinical cachexia imaging modalities such as
CT are frequently used to determine muscle mass
[26, 27]. For rodents micro-CT is available as a non-
invasive method for screening anatomical change
[28]. High spatial resolution and temporal resolu-
tion allow capture of detailed anatomical imaging
and monitor disease progression in rodents [28, 29].
The absorbed radiation dose from serial micro-CT
imaging is low and likely below the threshold for
carcinogenesis [30]. This makes micro-CT analysis
an interesting novel approach in the assessment of
muscle weight loss in experimental cancer cachexia.
Hind limb imaging was performed in all ani-
mals prior to the start of the experiment, and once
more directly preceding sacrifice. Under anesthesia
by isoflurane inhalation animals were positioned on
the left flank, and had their right hindlimb fixed in
extended position. Images were obtained using a
Quantum FX (Perkin Elmer, Waltham, MA, USA)
low-dose micro computed tomography (CT) scan-
ner which scanned at 90 kV of peak voltage, with
160 A of current, 40 mm field of view, and 4.5-
minute scan time. Obtained scans were subsequently
analyzed using Analyze 11.0 (Analyze Direct, Inc.,
Lenexa, KS, USA). This was done by manually delin-
eating the skeletal muscle of the right hindlimb from
the tibial surface proximally to the malleoli distally
and segmenting the tissue of interest based on HU
thresholds (–30 HU to +150 HU for skeletal muscle
[26]).
2.8. Bodyweight, muscle mass, and tumor size
Bodyweight was recorded daily. Bodyweight was
normalized to each animal’s bodyweight on day
0. Tumor size was recorded every other day start-
ing on day 9 after tumor inoculation using digital
calipers. Tumor mass was estimated via the for-
mula mass(mg) = tumor volume (mm3) = width2 ×
length/2 [31]. Animals were sacrificed by cervical
dislocation under isoflurane anesthesia on day 21
or upon body weight loss exceeding 20%. Gastroc-
nemius (GCM), tibialis anterior (TA) and soleus
(Sol) muscles of both hind legs and tumor were
dissected and weighed. Muscle weight from the
left and right hind leg were averaged to provide a
mean muscle weight (GCM, TA, and Sol) for each
animal. Muscle samples were immediately snap-
frozen in liquid nitrogen and stored at –80◦C until
analysis.
2.9. RNA isolation and real-time polymerase
chain reaction
Cancer-cachexia associated muscle wasting is
known to be most pronounced in fast-twitch type
II-containing muscles, such as GCM and TA [32].
Therefore, for gene expression analysis, total RNA
was isolated from snap-frozen GCM muscle tissue
using Trizol reagent (Invitrogen, Breda, the Nether-
lands), and subsequently purified by DNase treatment
(RQ1 RNase-Free DNase) (Promega Benelux B.V.,
Leiden, the Netherlands). 1 g of total RNA was
reversed transcribed to cDNA using random hex-
amer primers (Invitrogen, Breda, the Netherlands),
and Superscript II RT (Invitrogen, Breda, the Nether-
lands). Quantitative real-time polymerase chain
reaction (RT-PCR) was performed using an iCy-
cler real-time PCR system (Biorad, California, The
United States of America) using SYBR Green
(Sigma-Aldrich, St. Louis, The United States of
America). Used primer sequences can be found in
Table 2. GAPDH was used as housekeeping gene for
normalization. Relative gene expression fold change
was calculated with the comparative delta-delta
Ct method (2−Ct)/(average 2−Ct(healthy controls))
[33]. Each sample was tested in duplicate.
Table 2
Reverse transcription-polymerase chain reaction primer sequences
Gene Forward primer Reverse primer Genbank accession
number
Atrogin1 5′-GTTTTCAGCAGGCCAAGAAG 5′-TTGCCAGAGAACACGCTATG AF 441120
MyoD 5′-AAACCCCAATGCGATTTATCAGG 5′-TAAGCTTCATCTTTTGGGCGTGA NM 010866
Myogenin 5′CACTCCCTTACGTCCATCGT 5′-CAGGACAGCCCCACTTAAAA NM 031189
Murf1 5′-AGGTGTCAGCGAAAAGCAGT 5′-CCTCCTTTGTCCTCTTGCTG NM009066
GAPDH 5′-ATGCATCCTGCACCACCAACT 5′-CAGTGATGGCATGGACTGTG NM 008084
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2.10. Statistics
Categorical data are expressed as number (per-
centage) and continuous variables as mean ± SEM
(normal distribution, visually assessed and by means
of the Shapiro-Wilks test). Body weight and grip-
strength were normalized to each animal’s body
weight and grip-strength respectively on day 0. Mus-
cle weight from the left and right hind leg were
averaged to provide a mean GCM and TA muscle
weight for each animal. Multiple group comparisons
were done by one-way ANOVA with a Bonferroni’s
posthoc test. Spearman-Rho rank correlation coeffi-
cient was used for testing bivariate correlations. All
analyses were performed using IBM SPSS Statistics
for Windows, version 21.0 (IBM Corp., Armonk, NY,
USA). A P value <0.05 was considered statistically
significant.
3. Results
To study the effects of a quercetin supplemented
diet, thirty CD2F1 mice were randomly allocated
to three groups, i.e. non-tumor bearing (NTB) with
access to regular chow, tumor-bearing (TB) with
access to regular chow, and tumor-bearing with
access to chow supplemented with 250 mg quercetin
Fig. 1. Daily bodyweight throughout the experiment. Line chart
depicting the mean ± SEM daily bodyweights per group in
non-tumor-bearing male CD2F1 mice (NTB, n = 10), C26 tumor-
bearing (TB, n = 10) mice with ad libitum access to regular chow,
and C26 TB mice with ad libitum access to quercetin supple-
mented chow (TB + Q, n = 10). Bodyweight was normalized to
each animal’s bodyweight on day 0 and is expressed as the per-
cental difference. Mice in the TB group experienced a significant
loss of bodyweight in comparison to both TB + Q and NTB mice.
per kg chow (TB + Q), starting on the first day of the
experiment. Simultaneously, mice allocated to tumor-
bearing groups were inoculated subcutaneously with
0.5 × 106 C26 adenocarcinoma cells. Body weight
was recorded daily. During the experiment NTB
mice gained 9.4 % bodyweight, whereas TB mice
lost 3.9% bodyweight (p < 0.0001) (Fig. 1). Tumor-
bearing mice showed a decrease in body weight on
the first day after changing the diet to quercetin sup-
plemented, likely as a result of the different taste
of this diet. Thereafter, however, they gained 5.3%
bodyweight, which was significant when compared
to tumor-bearing mice on a regular diet (p = 0.0024).
Daily food intake was relatively constant for non-
tumor-bearing mice throughout the experiment with
a mean daily intake of 3.8 g chow per mouse (Fig. 2).
For tumor-bearing mice, on a regular diet, com-
parable food intake was observed during the first
two weeks of the experiment. Throughout the last 7
days of the experiment, these mice showed a grad-
ual increase in daily food intake up to a mean of
7.9 g chow per mouse on the last timepoint. Mice on
the quercetin diet had an increased intake throughout
the experiment, starting rapidly after initiation of this
Fig. 2. Daily food intake throughout the experiment. Line chart
depicting the mean daily food intake over the prior 24 hours per
group in non-tumor-bearing male CD2F1 mice (NTB, n = 10), C26
tumor-bearing (TB) mice with ad libitum access to regular chow
(C26 TB, n = 10) and mice with ad libitum access to quercetin
supplemented chow (TB + Q, n = 10). Food intake was measured
per cage and subsequently averaged per mouse. Food intake is
expressed in grams (g). Food intake of TB mice was comparable
to NTB mice throughout the first two weeks, subsequently, daily
chow consumption more than doubled. TB + Q mice had an overall
higher chow consumption throughout the first two weeks, subse-
quently, a minor increase in chow consumption was observed in
the final days of the experiment.
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diet, resulting in a mean daily intake of 4.7 g chow
per mouse during the first two weeks of the experi-
ment. These tumor-bearing mice on a quercetin diet
too were observed to increase their daily food intake
during the last 7 days of the experiment, up to a max-
imum mean of 6.2 g chow per mouse on the 20th day
of the experiment.
3.1. Grip-strength assessment
Grip-strength was assessed twice per week. NTB
mice showed an increase in grip-strength over the
course of the experiment. This increase registered up
to 24.7% at the end of the experiment (Fig. 3). TB
mice, on the other hand, showed a limited increase
of 6.7% at the end of the experiment, this difference
did not reach significance (p = 0.06). Tumor-bearing
mice on a quercetin supplemented diet had a com-
parable grip-strength to the tumor-bearing mice on a
regular chow diet. These mice too showed a limited
increase in grip-strength of 7.6%.
3.2. Micro-CT hindlimb skeletal muscle
volumetry
Hind limb skeletal muscle volumetric measure-
ments by micro-CT (Fig. 4A) on day 1 were
comparable for all three groups; 245.6 mm3 for
NTB mice, 242.0 mm3 for TB mice, and 250.1 mm3
Fig. 3. Relative grip-strength at the end of the experiment. Bar
graphs depicting the mean ± SEM for final grip-strength normal-
ized to starting grip-strength in non-tumor-bearing male CD2F1
mice (NTB, n = 10), C26 tumor-bearing (TB) mice with ad libitum
access to regular chow (C26 TB, n = 10) and mice with ad libitum
access to quercetin supplemented chow (TB + Q, n = 10). Multiple
group comparisons were done by one-way ANOVA with a Bonfer-
roni’s posthoc test. All groups were compared against TB mice. A
substantial, non-significant difference in relative grip-strength was
observed between TB and NTB mice. TB + Q relative grip-strength
was comparable to TB mice.
for TB + Q mice (Fig. 4B). No significant change
was observed in skeletal muscle volume on day 21
for NTB mice and TB + Q mice; 253.8 mm3 for
NTB mice, and 249.6 mm3 for TB + Q mice. Tumor-
bearing mice on a regular chow diet experienced a
decrease in skeletal muscle volume to 212.8 mm3 on
day 21 (p = 0.006). These differences between NTB
and TB, as well as TB + Q and TB, were significant
Fig. 4. Micro-CT hindlimb skeletal muscle mass volumetric. (A) Micro-CT image depicting the hindlimb musculature. (B) Bar graphs
depicting the mean ± SEM for micro-CT skeletal muscle volume on day 1 and day 21 respectively in non-tumor-bearing male CD2F1 mice
(NTB, n = 10), C26 tumor-bearing (TB) animals with ad libitum access to regular chow (C26 TB, n = 10)and mice with ad libitum access
to quercetin supplemented chow (TB+Q, n = 10). Multiple group comparisons were done by one-way ANOVA with a Bonferroni’s posthoc
test. All groups were compared against TB mice. Comparisons between multiple time-points were done by paired samples t-test. *p < 0.05
**p < 0.01.
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with respective p-values of 0.0078 and 0.0172. A
high positive correlation is observed between skele-
tal muscle volume on day 21 and combined right
hindlimb muscle weight (GCM, TA, and Sol) at sac-
rifice (Spearman’s rho = 0.718, p < 0.0001).
3.3. Muscle and tumor weight
All animals were sacrificed at 21 days following
tumor inoculation. The gastrocnemius and tibialis
anterior muscles were resected and weighed. Mean
gastrocnemius muscle weight in NTB mice was
175.2 ± 12.4 mg versus 125.5 ± 27.3 in TB mice
(p < 0.0001, Fig. 5B). Mean gastrocnemius mus-
cle weight in TB + Q mice was 171.3 ± 17.8 mg
(p < 0.0001 compared to TB mice). Mean tib-
ialis anterior muscle weight in NTB mice was
64.1 ± 7.1 mg versus 48.9 ± 11.1 in TB mice
(p = 0.0024, Fig. 5D). Mean tibialis anterior muscle
weight in TB + Q mice was 63.7 ± 9.6 mg (p = 0.0031
compared to TB mice). Tumor mass increased until
at day 21 a mean tumor weight of 478.3 ± 288.7 mg
was recorded for TB mice and 288.7 ± 196.3 mg
for TB + Q mice (p = 0.14) (Fig. 5C). Tumor mass
was not correlated with tibialis anterior muscle
weight (Spearman’s rho = –0.261, p = 0.47) and gas-
trocnemius muscle weight (Spearman’s rho = 0.091,
p = 0.80) at sacrifice for TB + Q mice (Fig. 5E, 5F).
3.4. Gene expression
Skeletal muscle E3 ubiquitin ligases and myogenic
regulatory factors mRNA expression profiles were
determined in gastrocnemius muscle samples. A sub-
stantial, non-significant difference in expression of
E3 ubiquitin ligase atrogin-1 was observed between
TB and TB + Q mice, as well as to a lesser extent in
the expression of MuRF1 (Fig. 6A, 6B). Expression
of MyoD and Myogenin was comparable between all
groups (Fig. 6C, 6D).
4. Discussion
Cancer-associated cachexia is a common finding
in patients afflicted by multiple types of malignan-
cies [27, 34]. It has detrimental effects on survival
as well as the quality of life [27, 34]. Unfortunately,
there are no validated treatment modalities to halt or
reverse the associated progressive muscle wasting.
Our study investigated whether quercetin supplemen-
tation could attenuate muscle wasting in the murine
C26 cancer-cachexia model. We found this to be
true. C26 tumor-bearing mice on a diet supplemented
with quercetin showed a preservation of gastroc-
nemius muscle weight as well as tibialis anterior
muscle weight. In this group of mice, bodyweight
was also preserved. These findings were accompa-
nied by a tendency towards decreased expression
of E3 ubiquitin ligases atrogin-1 and MuRF1 in
tumor-bearing mice on a quercetin supplemented diet
compared to tumor-bearing mice on a regular chow
diet. As this study was not powered to detect dif-
ferences in mRNA expression we consider it likely
this lack of significance is due to a type II error.
It has been shown that quercetin reduces the tran-
scription of atrogin-1 and MuRF1 in obesity-induced
skeletal muscle inflammation in mice, which has
been attributed to diminished activation of ERK,
p38 MAPK and NF-κB [24]. Another study also
reported NF-κB inactivation along with the upreg-
ulation of heme-oxygenase-1 (HO-1) in mice treated
with quercetin [35]. Despite preservation of muscle
mass and body weight, we did not observe a differ-
ence in grip-strength between TB and TB + Q mice.
Our findings are inline with the study of Velázquez
et al. [14]. They showed quercetin supplementation
to help preserve muscle mass and limit bodyweight
loss in an ApcMin/+ mice model. Furthermore, a
recent study reported similar muscle preservation
by quercetin treatment in nude mice with cachexia
induction via A459 cells, a human alveolar basal
epithelial adenocarcinoma cell line [36]. In con-
trast, C26 tumor-bearing mice given a cocktail of
antioxidants, including quercetin, showed acceler-
ated development of cachexia and even expedited
death [37]. In our study food intake was higher in
TB + Q mice compared to mice receiving control
chow. Velázquez et al. found no difference in chow
consumption between the quercetin-treated groups
[14]. This difference in food intake is not readily
explained. Although food intake of TB mice was
comparable to NTB mice throughout the first two
weeks, daily chow consumption more than doubled
during the final days of the experiment. Despite the
increased nutritional intake, a significant loss of body
weight was observed. This suggests a hypermetabolic
state for these mice, but was not quantified in this
study.
Quercetin is a natural, bioactive and readily
available flavonoid found in a selection of fruits,
vegetables and herbs [18], as well as over the
counter dietary supplements. The quercetin dose in
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Fig. 5. Bodyweight, muscle weight and tumor mass at sacrifice. Bar graphs depicting the mean ± SEM for (A) final bodyweight normalized
to starting bodyweight, (B) gastrocnemius muscle weight, (C) tumor weight, and (D) tibialis anterior muscle weight in non-tumor-bearing
male CD2F1 mice (NTB, n = 10), C26 tumor-bearing (TB) mice with ad libitum access to regular chow (C26 TB, n = 10) and mice with
ad libitum access to quercetin supplemented chow (TB+Q, n = 10). Multiple group comparisons were done by one-way ANOVA with a
Bonferroni’s posthoc test. All groups were compared against TB mice. Asterisk brackets are displayed for significant results only. ** p < 0.01
**** p < 0.0001. A possible tumor weight reduction in quercetin treated mice was noted, therefore the relationship between gastrocnemius
muscle weight and tumor weight, as well as tibialis anterior muscle weight and tumor weight, were assessed to demonstrate that a possible
reduction in tumor burden did not contribute to the attenuation in muscle atrophy. Scatter-dot plots depict no relationship between (E)
gastrocnemius muscle mass and tumor mass (Spearman’s rho = 0.091, p = 0.80) and (F) tibialis anterior muscle mass and tumor mass
(Spearman’s rho=–0.261, p = 0.47) in quercetin-treated mice. Considering these statistics, the attenuation in muscle atrophy cannot be
sufficiently explained by differences in tumor burden.
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Fig. 6. mRNA expression levels in cachectic muscle. Bar graphs depicting the mean ± SEM mRNA expression levels in gastrocnemius
muscle of (A) Atrogin-1, (B) MuRF1, (C) MyoD and (D) Myogenin in non-tumor-bearing male CD2F1 mice (NTB, n = 10), C26 tumor-
bearing (TB) mice with ad libitum access to regular chow (C26 TB, n = 10) and mice with ad libitum access to quercetin supplemented chow
(TB + Q, n = 10). Multiple group comparisons were done by one-way ANOVA with a Bonferroni’s posthoc test. All groups were compared
against TB mice. A substantial but non-significant difference in expression of E3 ubiquitin ligase atrogin-1, and to a lesser extent MuRF1,
was observed between TB and TB + Q mice.
the current study equates to a human equivalent
dose [38] of 2.85 mg/kg. For an average European
or Northern American adult [39], this would equate
to 202 mg or 230 mg quercetin respectively. Well
within the limits of what has been safely used in
prior studies [19, 40, 41], and below the thresh-
old of what is commercially available in over the
counter supplements in various western countries.
The human equivalent dose of the dosage we used
significantly exceeds the estimated 25–50 mg per day
consumed per day in a western diet [42]. Quercetin
has previously been used in studies, including ath-
letes, military personnel, and elderly persons, to
investigate its potential as a performance-enhancing
supplement. These studies yielded ambiguous results
with regard to lean body mass, basal metabolic rate,
total energy expenditure and VO2max [19, 40, 41, 43].
Moreover, quercetin has been investigated for its pos-
sible role as a senolytic compound with inconsistent
results [44, 45]. Although quercetin has been sug-
gested as a therapeutic candidate in cachexia [46], no
studies have been published on quercetin treatment
countering muscle wasting in humans [47]. Based on
the present study and the aforementioned research
by Velázquez et al. [14], quercetin supplementation
may aid in limiting muscle wasting in cancer patients.
Further research is however warranted to confirm its
anti-catabolic effects.
A substantial, non-significant difference in tumor
burden was observed between tumor-bearing mice
on a regular chow diet and tumor-bearing mice on a
quercetin supplemented diet. Anti-cancer effects of
quercetin have been previously reported, although
available evidence is limited [48–53]. In our study
we found a negligible, non-significant correlation
between tumor weight and muscle mass. However,
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we cannot exclude that the anti-tumor effect has
impacted on other outcome parameters, e.g. by selec-
tive down-regulation of tumor-derived mediators of
cachexia.
Using resected hindlimb muscle tissue at the end
of the experiment as gold standard we found a highly
positive correlation with micro-CT hindlimb skele-
tal muscle volume measurement. This technique was
found to be feasible and relevant in the current
study and may allow for quantitative assessment of
individual muscles, as well as allowing for tissue
composition quantification, i.e. assessment of fatty
infiltration of muscle.
Several limitations apply to the present study.
The study was powered on an expected reduction
in loss of muscle weight. As such, non-significant
differences in secondary outcome parameters (e.g.
relative mRNA expression levels) may have been sub-
ject to type II errors. Furthermore, survival was not
included as one of the endpoints due to the strict eth-
ical guidelines associated with the initiation of this
study.
In conclusion, dietary quercetin supplementation
limits bodyweight loss and prevents muscle wasting
in a murine C26-cancer-associated cachexia model.
These data add to a body of evidence support-
ing the use of quercetin to halt muscle wasting in
experimental cancer-associated cachexia models and
paving the way for clinical research on the efficacy
of quercetin in the attenuation of muscle wasting in
humans.
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